国际内分泌代谢杂志2024,Vol.44Issue(2) :128-131.DOI:10.3760/cma.j.cn121383-20230705-07007

糖尿病神经性骨关节病的诊治进展

Advances in the diagnosis and treatment of diabetic neuropathic osteoarthropathy

王毅 何岸苇 晁爱军
国际内分泌代谢杂志2024,Vol.44Issue(2) :128-131.DOI:10.3760/cma.j.cn121383-20230705-07007

糖尿病神经性骨关节病的诊治进展

Advances in the diagnosis and treatment of diabetic neuropathic osteoarthropathy

王毅 1何岸苇 2晁爱军3
扫码查看

作者信息

  • 1. 天津市天津医院神经内科,天津 300211
  • 2. 天津市天津医院放射一科,天津 300211
  • 3. 天津市天津医院骨内科,天津 300211
  • 折叠

摘要

糖尿病神经性骨关节病是一种严重影响足踝关节的致残性疾病,早期表现不典型,常导致治疗延误,以往多采用完全减压和制动,对于药物治疗关注不足.从药理机制研究角度发现,地舒单抗可能对于治疗该病有一定的效果.本文综述了该病的研究和诊治进展,以及国外采用地舒单抗治疗糖尿病神经性骨关节病的研究报道,以期丰富对该病的诊疗方法.

Abstract

Diabetic neuropathic osteoarthropathy is a debilitating disease that seriously affects the foot and ankle joints,with atypical early manifestations that often lead to delayed treatment,in the past,complete decompression and braking have been used,with insufficient attention to pharmacological treat-ment.Research into pharmacological mechanisms has shown that denosumab may be effective in treating this disease.This article reviews the progress of research on the diagnosis and treatment of diabetic neurological osteoarthropathy.It also discusses foreign research reports on the use of denosumab in the treatment of dia-betic neurological osteoarthropathy.

关键词

糖尿病/神经性骨关节病/地舒单抗

Key words

Diabetic/Diabetic neuropathic osteoarthropathy/Denosumab

引用本文复制引用

出版年

2024
国际内分泌代谢杂志
中华医学会,天津医科大学

国际内分泌代谢杂志

CSTPCD
影响因子:0.842
ISSN:1673-4157
参考文献量20
段落导航相关论文